ERBB2 and breast carcinoma: Inhibiting either pathway with specific inhibitors at a concentration selectively blocking the relevant pathway mimicked Gi/o-GPCR blockade by PTx in suppressing CSC activity and sensitizing CSCs to HER2-targeted therapy in HER2+ breast cancer cells.